Skip to main content

Advertisement

Log in

Hyperphosphatemia due to fosphenytoin in a pediatric ESRD patient

  • Brief Report
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

Fosphenytoin is indicated for the treatment of generalized convulsions and seizures occurring during neurosurgery. Metabolites of fosphenytoin include phenytoin, phosphate, and formaldehyde. The drug monograph recommends caution in administering fosphenytoin to patients in whom phosphate restriction is necessary. Additionally, fosphenytoin has altered pharmacokinetics in end-stage renal disease patients. We report a 17-year old African-American male with end-stage renal disease who developed acute hyperphosphatemia to 3.9 mmol/L (12.1 mg/dL) following the intravenous administration of 1000 mg of fosphenytoin for an idiopathic complex partial seizure. To our knowledge, this is the first report of acute hyperphosphatemia due to fosphenytoin administration. Due to this risk of hyperphosphatemia, we recommend that fosphenytoin should be used with caution in the end-stage renal disease population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Pfizer Inc (2002) Cerebyx (fosphenytoin sodium injection) [package insert]. Pfizer Inc, NY, pp 1–19

  2. Fischer JH, Patel TV, Fischer PA (2003) Fosphenytoin. Clinical pharmacokinetics and comparative advantages in the acute treatment of seizures. Clin Pharmacokinet 42:33–58

    Google Scholar 

  3. Aweeka FT, Gottwald MD, Gambertoglio JG, Wright TL, Boyer TD, Pollock AS, Eldon MA, Kugler AR, Allredge BK (1999) Pharmacokinetics of fosphenytoin in patients with hepatic or renal disease. Epilepsia 40:777–782

    CAS  PubMed  Google Scholar 

  4. Roberts WL, De BK, Coleman JP, Annesley TM (1999) Falsely increased immunoassay measurements of total and unbound phenytoin in critically ill uremic patients receiving fosphenytoin. Clin Chem 45:829–837

    CAS  PubMed  Google Scholar 

  5. Keegan MT, Bondy LR, Blackshear JL, Lanier WL (2002) Hypocalcemia-like electrocardiographic changes after administration of intravenous fosphenytoin. Mayo Clin Proc 77:584–586

    PubMed  Google Scholar 

  6. Fujisawa Healthcare, Inc (2003) Prograf (tacrolimus) [package insert]. Fujisawa Healthcare, Inc, Deerfield, IL, pp 1–55

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kevin D. McBryde.

Additional information

This work has been supported in part by the National Institutes of Health, National Center for Research Resources, Grant 1K12RR017613–01

Rights and permissions

Reprints and permissions

About this article

Cite this article

McBryde, K.D., Wilcox, J. & Kher, K.K. Hyperphosphatemia due to fosphenytoin in a pediatric ESRD patient. Pediatr Nephrol 20, 1182–1185 (2005). https://doi.org/10.1007/s00467-005-1947-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-005-1947-0

Keywords

Navigation